Insys Therapeutics (INSY): Pipeline Progressing - RBC

November 4, 2016 7:15 AM EDT
Get Alerts INSY Hot Sheet
Price: $9.37 -0.64%

Rating Summary:
    5 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade INSY Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

RBC Capital analyst, Randall Stanicky, reiterated his Sector Perform rating on shares of INSYS Therapeutics (NASDAQ: INSY) and cut his price target to $23 (from $26) after the company reported an uneventful 3Q with the focus of the call heavily geared towards pipeline, where it sees a number of near-term catalysts.

The analyst revisited his estimates with a more conservative view on Subsys and pushed out Syndros into mid-2Q given uncertainty around launch timing. This delay in profit recognition, pressures the price target down to $23 but leaves the analyst with an Outperform rating.

For an analyst ratings summary and ratings history on INSYS Therapeutics click here. For more ratings news on INSYS Therapeutics click here.

Shares of INSYS Therapeutics closed at $10.02 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change, Earnings

Related Entities

RBC Capital

Add Your Comment